4D Molecular Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that 4D Molecular Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.21M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $37.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $20.72M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.13M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $18.04M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $13.61M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $6.99M | Mar 25, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.21M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $37.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $20.72M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.13M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $18.04M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $13.36M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $6.96M | Mar 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($140.11M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($160.87M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($100.84M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($107.49M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($71.32M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($56.69M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($49.31M) | Mar 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($159.55M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($187.84M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($112.87M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($110.03M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($71.33M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($56.66M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($50.76M) | Mar 25, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($109.08M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($134.59M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($75.79M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($86.69M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($69.13M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($50.91M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($36.71M) | Mar 25, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $536.0K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.79M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $2.77M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $11.54M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.11M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.00M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.20M | Mar 25, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $566.71M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $560.38M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $339.89M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $261.85M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $353.49M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $288.33M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $58.23M | Mar 25, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.05M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $49.78M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $32.06M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $30.51M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $34.38M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $31.94M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $28.22M | Mar 25, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $505.66M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $510.61M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $307.83M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $231.34M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $319.11M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $256.39M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($72.97M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | ($27.59M) | Mar 25, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($716.30M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($576.20M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($415.33M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($314.49M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($207.00M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($135.68M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($79.03M) | Mar 25, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.24M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $149.34M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $249.11M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $52.35M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $153.00M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $276.73M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $49.65M | Mar 25, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.61M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 45.79M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 43.08M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 32.63M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 32.22M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 26.68M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 5.18M | Mar 25, 2021 |